SKI II (SPHINGOSINE KINASE INHIBITOR)
4-{[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino}phenol
CAS: 312636-16-1
Molecular Formula: C15H11ClN2OS
SKI II (SPHINGOSINE KINASE INHIBITOR) - Names and Identifiers
| Name | 4-{[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino}phenol |
| Synonyms | CS-1145 SphK-I2 SPHK-I2 SKI II - SKI 2 SKI II (SPHK-I2) SKI II (SphK-I2) SPHINGOSINE KINASE INHIBITOR Sphingosine Kinase Inhibitor SPHINGOSINE KINASE INHIBITOR 2 Sphingosine Kinase Inhibitor 2 SKI II (SPHINGOSINE KINASE INHIBITOR) 4-{[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino}phenol |
| CAS | 312636-16-1 |
| InChI | InChI=1/C15H11ClN2OS/c16-11-3-1-10(2-4-11)14-9-20-15(18-14)17-12-5-7-13(19)8-6-12/h1-9,19H,(H,17,18) |
SKI II (SPHINGOSINE KINASE INHIBITOR) - Physico-chemical Properties
| Molecular Formula | C15H11ClN2OS |
| Molar Mass | 302.78 |
| Density | 1.415±0.06 g/cm3(Predicted) |
| Boling Point | 507.1±60.0 °C(Predicted) |
| Flash Point | 260.5°C |
| Solubility | DMSO: ≥20mg/mL |
| Vapor Presure | 6.65E-11mmHg at 25°C |
| Appearance | solid |
| Color | off-white |
| pKa | 10.17±0.26(Predicted) |
| Storage Condition | 2-8°C |
| Sensitive | Air & Light Sensitive |
| Refractive Index | 1.709 |
| MDL | MFCD00733553 |
| Use | SKI II |
| In vitro study | SKI II acts on breast cancer cell line MDA-MB-231 and effectively inhibits endogenous SK activity. SKI II acts on human cancer cell lines, including T-24, MCF-7, MCF-7/VP, NCI/ADR, with significant anti-proliferative effects, IC50 of 4.6 μm and 1.2 μm respectively, 0.9 μm and 1.3 μm. SKI II also induced apoptosis in T24 cells, consistent with reduced S1P levels. SKI II acts on JC cells to reduce S1P formation, IC50 is 12 μm, and this effect is concentration-dependent. In addition, SKI II can reverse the resistance of SGC7901/DDP to Cisplatin by down-regulating the expression of P-gp and up-regulating apoptosis by down-regulating SPHK1. |
| In vivo study | The homologous Balb/c mouse solid tumor model carrying JC breast cancer cells was administered intraperitoneally or orally at a dose of 50 mg/kg by SKI II, which significantly reduced tumor growth compared with the control group, there was no apparent toxicity or weight loss. Intraperitoneal administration of SKI II to mice at a dose of 50 mg/kg ameliorated antigen-induced bronchial smooth muscle hyperresponsiveness by inhibiting endogenous S1P production. |
SKI II (SPHINGOSINE KINASE INHIBITOR) - Risk and Safety
| WGK Germany | 3 |
| RTECS | SK5900000 |
SKI II (SPHINGOSINE KINASE INHIBITOR) - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.303 ml | 16.514 ml | 33.027 ml |
| 5 mM | 0.661 ml | 3.303 ml | 6.605 ml |
| 10 mM | 0.33 ml | 1.651 ml | 3.303 ml |
| 5 mM | 0.066 ml | 0.33 ml | 0.661 ml |
Last Update：2024-01-02 23:10:35
SKI II (SPHINGOSINE KINASE INHIBITOR) - Reference Information
| Biological activity | SKI II (SphK-I2) is a highly selective, non-ATP competitive sphingosine kinase (SphK) inhibitor with an IC50 of 0.5 μM and no inhibitory effect on other kinases, including PI3K, PKCα and ERK2. |
| Target | Value |
| Sphingosine Kinase | 0.5 μM |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: SKI II Visit Supplier Webpage Request for quotationCAS: 312636-16-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: SKI II Visit Supplier Webpage Request for quotationCAS: 312636-16-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History